This is a summary of the European public assessment report (EPAR) for Vpriv. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vpriv.
Therapeutic Indication
### Therapeutic indication Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.
Therapeutic Area (MeSH)
ATC Code
A16AB10
ATC Item
velaglucerase alfa
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| velaglucerase alfa | N/A | 维拉苷酶α |
EMA Name
Vpriv
Medicine Name
Vpriv
Aliases
N/ANo risk management plan link.
